| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Gliclazide is a second-generation oral sulfonylurea hypoglycemic drug with a strong effect. Its mechanism is similar to that of tolbutamide, that is, it selectively acts on islet β cells and its effect is more than 10 times stronger than that of tolbutamide. It has a hypoglycemic effect on adult diabetic patients, can reduce platelet adhesion, reduce plasma specific viscosity, reduce ADP-induced platelet aggregation, and improve nail fold microcirculation. In addition, experiments have shown that this product reduces cholesterol accumulation and reduces plasma concentrations of aortic triphosphate glycerides and fatty acids. Therefore, the combination of the two can not only treat diabetic metabolic disorders, but also prevent vascular disease, improve retinopathy and renal function. For adult-onset diabetes, diabetes with obesity or with vascular disease.
|
|
Foreign name gliclazide Molecular formula C15H21N3O3S Molecular weight 323.41 Appearance white crystal or crystalline powder CAS accession number 21187-98-4 EINECS accession number 244-260-5 Density 1.35 g/cm³ Melting point 163 to 169 ºC |
){kind=link}